Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Central nervous system involvement in malignant melanoma.

S Retsas1, A R Gershuny

  • 1Medical Oncology Unit, Westminster Hospital, London, UK.

Cancer
|May 1, 1988
PubMed
Summary

Malignant melanoma brain metastases impact survival, with some patients showing lesion regression or stability after treatment. Discussing therapeutic options is crucial for patients diagnosed with central nervous system (CNS) involvement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The treatment of melanoma at Westminster Hospital in the 20th century.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2013
Same author

Progress but not enough: the 2009 (7th) revision of the American Joint Committee on Cancer (AJCC) for melanoma staging and classification.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2011
Same author

Aristotle and Darwin. Parallel lives.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2009
Same author

Trauma as an etiologic factor of primary bone lymphoma: a report of 4 cases.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007
Same author

Systemic treatment of melanoma: quo vadis oncologist?

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007
Same author

The CDKN2A tumour suppressor gene: no mutations detected in patients with melanoma and additional unrelated cancers.

Melanoma research·2002

Area of Science:

  • Oncology
  • Neurology
  • Dermatology

Background:

  • Malignant melanoma can metastasize to the central nervous system (CNS), significantly impacting patient prognosis.
  • Understanding the clinical course and survival of patients with cerebral metastases is essential for treatment planning.

Purpose of the Study:

  • To analyze survival, treatment response, and disease characteristics in patients with cerebral metastases from malignant melanoma.
  • To provide insights into the prognosis and long-term outcomes for this patient population.

Main Methods:

  • Retrospective study of 100 consecutive patients with cerebral metastases from malignant melanoma.
  • Evaluation of survival from CNS involvement diagnosis, treatment response, primary lesion characteristics, and disease progression.

Main Results:

  • Median survival for all patients was 2.5 months.
  • Objective regression of cerebral lesions was observed in 10% of patients, with a median survival of 11.5 months post-CNS diagnosis.
  • 11% of patients had stable CNS disease for a median of 7 months.
  • 8% survived over 1 year, and 4% survived over 2 years from cerebral metastases diagnosis.

Conclusions:

  • Malignant melanoma metastatic to the brain has a generally poor prognosis, with a low median survival.
  • A small subset of patients may experience significant long-term survival and objective responses to treatment.
  • Patients diagnosed with brain metastases from malignant melanoma should be informed about available therapeutic options.

Related Experiment Videos